Liquidia enters exclusive US license with Vectura for treprostinil nebulizer product
Liquidia Technologies, a wholly owned subsidiary of Liquidia, signed an exclusive US license with Vectura Limited on October 27, 2025, to develop, make and sell treprostinil products, including L606, delivered through Vectura's nebulizer device. Vectura will supply clinical and commercial device supplies, and Liquidia Technologies will owe an upfront payment, milestone payments and royalties. The filing does not report financial results from the deal.
Key points
- Upfront payment of $2 million due at signing of the License Agreement
- Development milestone payments of up to $12 million and sales milestone payments of up to $92.5 million
- Royalties at middle single-digit rates tied to commercial sales in the US
- Either party may terminate for material breach or bankruptcy; Vectura may terminate if Liquidia Technologies challenges its patents
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.